Michael Gilman, PhD, has served as a member of our board of directors since November 2013. Dr. Gilman is currently Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016. He also serves on the Board of Directors of Obsidian Therapeutics, Inc. and Novartis Venture Fund, and on the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. From October 2016 to April 2019, he served as Chief Executive Officer for Obsidian Therapeutics, Inc. Previously, from 2014 to 2016, Dr. Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Dr. Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Dr. Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Dr. Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. Dr. Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a PhD in Biochemistry from University of California, Berkeley, and a SB in life sciences from Massachusetts Institute of Technology.
What is Michael Gilman's net worth?
The estimated net worth of Michael Gilman is at least $2.50 million as of May 29th, 2025. Dr. Gilman owns 55,216 shares of Scholar Rock stock worth more than $2,495,763 as of December 4th. This net worth estimate does not reflect any other assets that Dr. Gilman may own. Learn More about Michael Gilman's net worth.
How do I contact Michael Gilman?
Has Michael Gilman been buying or selling shares of Scholar Rock?
Michael Gilman has not been actively trading shares of Scholar Rock within the last three months. Most recently, Michael Gilman sold 3,375 shares of the business's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $29.72, for a transaction totalling $100,305.00. Following the completion of the sale, the director now directly owns 55,216 shares of the company's stock, valued at $1,641,019.52. Learn More on Michael Gilman's trading history.
Who are Scholar Rock's active insiders?
Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), and Akshay Vaishnaw (President, R&D). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?
In the last year, Scholar Rock insiders bought shares 2 times. They purchased a total of 500,439 shares worth more than $18,807,336.03. In the last year, insiders at the sold shares 24 times. They sold a total of 405,963 shares worth more than $14,753,847.01. The most recent insider tranaction occured on October, 6th when Director Srinivas Akkaraju bought 113,025 shares worth more than $4,368,416.25. Insiders at Scholar Rock own 13.3% of the company.
Learn More about insider trades at Scholar Rock. Information on this page was last updated on 10/6/2025.
